inmunoadmin

ERAP1-dependent extreme antigen processing efficacy can govern MHC class I expression hierarchy

by

J Immunol. 2025 Mar 27:vkaf013. doi: 10.1093/jimmun/vkaf013. Online ahead of print. ABSTRACT Peptide presentation by major histocompatibility complex (MHC) class I molecules enables CD8+ T lymphocytes to monitor the intracellular proteome of tissue cells. CD8+ T cell priming and acquisition of effector functions is affected by cognate peptide-MHC-I complex density on the cell surface, which … Read more

Transcriptional and chromatin accessibility landscapes of hematopoiesis in a mouse model of breast cancer

by

J Immunol. 2025 Mar 27:vkaf026. doi: 10.1093/jimmun/vkaf026. Online ahead of print. ABSTRACT Increased myeloid lineage production, termed myeloid skewing, leading to decreased tumor immunity, is a hallmark of aberrant hematopoiesis associated with cancer. It is believed that myeloid skewing may occur at the hematopoietic stem and progenitor cells (HSPCs) level to elicit hematopoietic changes. However, … Read more

DOCK2 Deficiency and GATA2 Haploinsufficiency Can Underlie Critical Coronavirus Disease 2019 (COVID-19) Pneumonia

by

J Clin Immunol. 2025 Mar 28;45(1):85. doi: 10.1007/s10875-025-01877-z. ABSTRACT The life-threatening coronavirus disease 2019 (COVID-19) affects about 1 in 1,000 healthy people under 50 without underlying conditions. Among patients with critical COVID-19 pneumonia, rare germline variants at genes controlling type I IFN immunity have been reported in up to 5% of patients. Causal etiologies in … Read more

Harnessing microglia-based cell therapies for the treatment of neurodegenerative diseases

by

Curr Opin Immunol. 2025 Mar 25;94:102552. doi: 10.1016/j.coi.2025.102552. Online ahead of print. ABSTRACT Given the growing evidence linking microglia to the onset and progression of various neurodegenerative diseases, these brain-resident macrophages have emerged as a promising cell type for targeted therapeutic interventions. This review highlights recent studies that utilized innovative, microglia-focused strategies for the treatment … Read more

Hippo-YAP pathway regulates antimicrobial immune response in obscure puffer Takifugu obscurus

by

J Immunol. 2025 Mar 26:vkaf011. doi: 10.1093/jimmun/vkaf011. Online ahead of print. ABSTRACT The Hippo signaling pathway plays an important role in regulating host immune responses. However, few studies have explored its role in fish. Therefore, this study aimed to investigate the mechanism by which the Hippo pathway regulates the expression of antimicrobial peptides (AMPs) in … Read more

Metabolic Adaptations Driving Innate Immune Memory: Mechanisms and Therapeutic Implications​Dan Hao on 26 de March de 2025 at 10:00

by

J Leukoc Biol. 2025 Mar 26:qiaf037. doi: 10.1093/jleuko/qiaf037. Online ahead of print. ABSTRACT Immune memory is a hallmark of the adaptive immune system. However, recent research reveals that innate immune cells also retain memory of prior pathogen exposure that prompts enhanced responses to subsequent infections. This phenomenon is termed “innate immune memory” or “trained immunity.” … Read more

Eph receptors activate myeloid checkpoint receptor LILRB5 to support tumor development

by

Cancer Immunol Res. 2025 Mar 27. doi: 10.1158/2326-6066.CIR-24-0737. Online ahead of print. ABSTRACT Immunosuppressive myeloid cells are critical obstacles to T cell-centered immune checkpoint blockade therapies, which have been successful in treating a fraction of cancer patients. How tumor cells interact with myeloid cells to regulate immune responses and tumor development is unclear. Here, we … Read more

Anti-CTLA4 therapy leads to early expansion of a peripheral Th17 population and induction of Th1 cytokines

by

Cancer Immunol Res. 2025 Mar 27. doi: 10.1158/2326-6066.CIR-24-1055. Online ahead of print. ABSTRACT The systemic immunological effects of combining anti-CTLA4 therapy with PD-(L)1 blockade remain incompletely characterized, despite the widespread use of this combination in treating various solid tumors across multiple stages of disease. Herein, we investigated the additive impact of anti-CTLA4 on peripheral immune … Read more

Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy

by

J Clin Immunol. 2025 Mar 27;45(1):84. doi: 10.1007/s10875-025-01873-3. ABSTRACT PURPOSE: The safety and tolerability of elapegademase (elapegademase-lvlr; Revcovi®) a PEGylated recombinant adenosine deaminase (ADA), were demonstrated in two Phase 3 clinical trials in the U.S. and Japan in patients with ADA-deficient severe combined immunodeficiency (ADA-SCID). Elapegademase replaced Adagen® (pegademase, a PEGylated bovine ADA) in 2018. … Read more

Diabetes can impact cellular immunity in solid tumors. Malgorzata A Garstka

by

Trends Immunol. 2025 Mar 24:S1471-4906(25)00057-2. doi: 10.1016/j.it.2025.02.014. Online ahead of print. ABSTRACT Cancer is increasingly prevalent worldwide, often coexisting with type 2 diabetes (T2D). Recent breakthroughs reveal the immune system’s pivotal role in eliminating tumors and how the metabolic environment, such as glucose availability, affects antitumor immunity. Diabetes is known to dysregulate both innate and … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri 301 Moved Permanently

301 Moved Permanently

nginx/1.24.0 (Ubuntu)